April FDA approvals split the spotlight between obesity and animal health

April 2026 FDA approvals tell two very different stories, one in mainstream biopharma and one in animal health. The headline-grabbing approval was Eli Lilly’s Foundayo (orforglipron), a once-daily oral GLP-1 for chronic weight management in adults, cleared on April 1 through an expedited FDA pathway. But for veterinary professionals, the more practical April developments came from FDA’s Center for Veterinary Medicine, which logged four animal drug approvals across cats, dogs, sheep, and horses during the month. (fda.gov)

On the human side, FDA said Foundayo was the first new molecular entity approved under the Commissioner’s National Priority Voucher pilot and the fastest such approval since 2002, with the decision issued 50 days after filing and well ahead of the application’s January 20, 2027 PDUFA date. Lilly positioned the product as the only GLP-1 pill for weight loss that can be taken without food or water restrictions, a convenience point that may help explain why oral obesity drugs are drawing intense commercial and clinical attention. (fda.gov)

The veterinary April approvals were quieter, but directly relevant to practice. FDA’s recent animal drug approvals page shows four April actions: AMODIP (amlodipine besylate tablets) for control of systemic hypertension in cats on April 29; a moxidectin oral drench for sheep parasites on April 29; Loxicom (meloxicam oral suspension) for pain and inflammation associated with osteoarthritis in dogs on April 20; and Gastrobim (omeprazole) on April 6 for treatment and prevention of recurrence of gastric ulcers in horses and foals 4 weeks of age and older. (fda.gov)

Foundayo’s approval drew the broader industry reaction. Lilly said shipping would begin April 6, initially through LillyDirect and then through retail pharmacies and telehealth channels. In the company announcement, Deborah Horn of UTHealth Houston said a once-daily pill without food or water restrictions could offer patients more flexibility, while Obesity Action Coalition CEO Joe Nadglowski said new options expand choice and may help more people find treatment that fits their lives. FDA’s acting CDER director, Tracy Beth Høeg, also emphasized that the product gives people with overweight or obesity another option through a faster review process. (investor.lilly.com)

There are also important caveats. Foundayo’s prescribing information lists common adverse reactions including nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, reflux, flatulence, and hair loss. Coverage, access, and comparative efficacy versus injectable GLP-1s remain open questions, and outside reporting has noted that oral competitors are already battling for formulary position and market share. STAT, for example, reported that Novo Nordisk’s oral Wegovy pill entered the market earlier and may shape uptake, while coverage and head-to-head comparisons remain unsettled. (pi.lilly.com)

Why it matters: For veterinary teams, the direct news is the steady expansion of labeled therapies in companion and food animals. A labeled feline hypertension drug matters because hypertension is common, underdetected, and often tied to chronic kidney disease and hyperthyroidism in older cats. A canine osteoarthritis approval matters because pain management remains one of the highest-volume needs in small-animal practice. More broadly, the Foundayo story matters because it keeps obesity treatment in the public conversation. As oral GLP-1s become more visible in human medicine, veterinarians should expect more pet parents to ask about obesity as a chronic disease, not just a lifestyle issue, and to press for practical, long-term management plans for their pets. That doesn’t mean human GLP-1 products translate into veterinary use, but it does mean expectations around weight management are changing. (fda.gov)

The regulatory contrast is notable, too. Human drug approvals can reshape public awareness overnight, especially in high-demand categories like obesity. Animal drug approvals tend to arrive with less fanfare, even when they solve everyday clinical problems. For veterinary professionals, that makes FDA’s CVM approval feed worth monitoring closely: the most consequential updates for practice may not trend widely, but they can still change prescribing options, client conversations, and standards of care. (fda.gov)

What to watch: In the near term, watch for FOI summaries and post-launch uptake around the April animal approvals, and for any spillover from the human obesity-drug boom into veterinary demand for better evidence, clearer counseling, and eventually more species-specific weight-management therapeutics. (fda.gov)